Stabilized single domain antibodies
US-2015064182-A1 · Mar 5, 2015 · US
Polypeptide constructs including VHH directed against EGFR for intracellular delivery
US9243065B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9243065-B2 |
| Application number | US-48768409-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 19, 2009 |
| Priority date | Nov 8, 2002 |
| Publication date | Jan 26, 2016 |
| Grant date | Jan 26, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further relates to a method for delivering therapeutic molecules to the interior of cells. The invention further relates to polypeptide constructs including VHH directed against EGFR.
First claim
Opening claim text (preview).
The invention claimed is: 1. A polypeptide construct comprising at least one Camelidae VHH that specifically binds EGFR, and at least one therapeutic polypeptide, agent, or antigen, wherein the therapeutic polypeptide or agent comprises a drug or a toxic compound, wherein said polypeptide construct internalizes upon binding to EGFR, and wherein the Camelidae VHH that specifically binds EGFR consists of any one of SEQ ID NOs: 31, 43 and 44 or a VHH that binds to the same epitope as one of SEQ ID NOs: 31, 43 and 44. 2. The polypeptide construct of claim 1 , wherein the Camelidae VHH that specifically binds EGFR is a humanized Camelidae VHH. 3. A composition comprising the polypeptide construct of claim 1 , and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Immunomodulators · CPC title
Drugs for disorders of the blood or the extracellular fluid · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9243065B2 cover?
- The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further relates to a method…
- Who is the assignee on this patent?
- Silence Karen, Vaeck Mark, Van Bergen En Henegouwen Paul M P, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2863. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).